Healthy Clinical Trial
Official title:
A Safety, Tolerability and Bioavailability Study of Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg) Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Autoimmune diseases happen when
the immune system does not identify part of the body as belonging to it. The immune system
then destroys that part as if it were an unknown tissue in the body. In T1DM, the body kills
the cells in the pancreas that produce insulin. Insulin is the hormone that "unlocks" the
cells of the body. It allows glucose to enter and fuel them. Special cells in the body
called islets make the insulin. Since glucose cannot enter the cells, it builds up in the
blood. The body's cells literally starve to death. Children are at risk of developing T1DM
and the risk is much higher than other severe, chronic childhood diseases. The only
treatments are a careful diet, planned physical activity, and testing blood sugar levels
several times a day. The patient must also inject insulin each day or use an insulin pump.
There is no cure for T1DM. Insulin injections are considered life support, because going
without insulin for just a few days causes the blood to have too much acid in it and that
can lead to death. On the other hand, taking too much insulin makes blood sugar levels go
too low, and if untreated, can lead to death as well.
DiaKine is developing Lisofylline to treat the failed immune system. This is what caused
T1DM in the first place and it does not go away. The purpose of this study is to see how
safe the study drug is. The study is also going to compare the levels of study drug in the
blood and to measure the effect of the study drug on other substances in the blood that are
linked to type 1 diabetes. These levels will be measured after the study drug is given as an
injection under the skin and an injection into the vein. To date, Lisofylline has been
tested when given as an injection in the vein.
The investigators hypothesize that Lisofylline will be safe when given as an injection under
the skin and in the vein and that levels of study drug will be very similar when given as an
injection under the skin and in the vein.
The investigators also hypothesize that Lisofylline will have a positive effect on the
substances in the blood that are linked to type 1 diabetes.
Compound: Lisofylline
Protocol Number and Title: DT-002: A Safety, Tolerability and Bioavailability Study of
Lisofylline After Continuous Subcutaneous (12 mg/kg) and Intravenous (12 mg/kg)
Administration in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Clinical Trial Phase: Phase 1 / Phase 2A
Study Objectives: The primary objective of this study is to assess safety and tolerability
of Lisofylline (LSF) in healthy adult subjects and in adult subjects with type 1 diabetes
mellitus (DM) following a single dose of LSF 12 mg/kg administered as a continuous
subcutaneous (s.c.) infusion over 24 hours, versus a single dose of LSF 12 mg/kg
administered as a continuous intravenous (i.v.) infusion over 24 hours.
The secondary objectives of this study are (1) to determine the bioavailability of a single
dose of LSF 12 mg/kg administered as a continuous s.c. infusion over 24 hours compared to
that of a single dose of LSF 12 mg/kg administered as a continuous i.v. infusion over 24
hours; and (2) an exploratory evaluation of the early efficacy of LSF based upon evaluation
of pharmacodynamic (PD) data.
Principal Investigator and Study Site:
Benno G. Roesch, MD Advanced Biomedical Research, Inc. Clinical Research Center 241 Main
Street Hackensack, New Jersey 07601 USA
Number of Subjects and Subject Population:
Up to 8 male or female subjects (up to 4 healthy adult male or female subjects and up to 4
male or female subjects with type 1 DM) will be enrolled as two separate cohorts into the
study to ensure a total of at least 6 evaluable subjects.
Healthy male or female subjects between 18-45 years of age, inclusive, and male or female
subjects, 18-45 years of age, inclusive, with a clinical diagnosis of type 1 DM for a
minimum of 2 years, requiring treatment with insulin, and no other clinically significant
exclusionary disease or conditions, are eligible to participate in the study.
Study Design: This is an open-label, single-dose, randomized, two-period, two-treatment,
crossover study in healthy subjects and in subjects with type 1 DM.
Eligible subjects will be admitted to the Clinic the evening prior to dosing (Day -1, Day 6)
during each treatment period, receive their assigned dose of study drug on Day 1 and Day 7,
and will remain confined to the Clinic until approximately 48 h following the start of study
drug administration (Day 3, Day 9). A washout period of three days will separate the two
treatment periods. All subjects will receive a single dose of LSF 12 mg/kg administered via
continuous i.v. infusion over a 24-hour period during one treatment period and a single dose
of LSF 12 mg/kg administered via continuous s.c. infusion over a 24-hour period during the
alternate treatment period.
Healthy subjects and subjects with type 1 DM will comprise two separate cohorts. All
subjects will be assigned a treatment sequence according to a randomization schedule that
will balance sequence assignments within the two cohorts.
Study Duration: The overall duration of the study for each subject is approximately 30 days.
This includes a 21-day screening period, two active treatment periods of three days each
separated by a 3-day washout period.
Study Drug: The drug product, LSF for injection, will be supplied by the Sponsor or designee
as a 120 mg/mL sterile solution (600 mg LSF/5 mL) in USP type 1 molded clear glass vials.
Each subject will receive a single dose of LSF 12 mg/kg as a continuous s.c. infusion over
24 hours during one period, and a single dose of LSF 12 mg/kg as a continuous i.v. infusion
over 24 hours during the alternate period in a randomized fashion.
Treatment Groups: There will be two treatment groups: LSF 12 mg/kg as a continuous s.c.
infusion over 24 hours and LSF 12 mg/kg as a continuous i.v. infusion over 24 hours.
Study Procedures: After providing written informed consent, subjects will undergo a complete
medical history, medication history, physical examination, vital signs evaluation, resting
12 lead electrocardiogram (ECG), clinical laboratory tests [chemistry, hematology,
urinalysis, HIV, Hepatitis B & C diagnostic profile and urine drug, alcohol and pregnancy
(females only) screen,] within 21 days prior to receiving the first dose of study drug.
On Days 1 and 7, eligible subjects will receive a single dose of LSF 12 mg/kg administered
via continuous i.v. infusion over a 24-hour period during one treatment period and a single
dose of LSF 12 mg/kg administered via continuous s.c. infusion over a 24-hour period during
the alternate treatment period.
Seated blood pressure and pulse rate will be measured on Days 1-3 and 7-9 within 15 min
prior to the start of infusion and 1, 4, 12, 24, 36 and 48 h following the start of
infusion. A resting 12-lead ECG will be performed on Days 1-2 and Days 7-8 at 1, 8 and 24 h
following the start of infusion, and prior to discharge from the Clinic on Day 9. An
abbreviated physical examination will be performed on Day 3, prior to discharge from the
Clinic and a complete physical examination will be performed on Day 9, prior to discharge
from the study. Adverse events (AEs) will be monitored by nursing and medical observations
and spontaneous reporting throughout the study. In addition, skin irritation assessments
will be performed on Days 1-2 and Days 7-8 within 15 min prior to the start of infusion and
2, 4, 8, 12 and 24 h following the start of infusion.
Blood will be collected for determination of plasma LSF concentration on Days 1-2 and Days
7-8 within 0.5 h prior to the start of infusion (time 0) and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6,
8, 10, 12, 18 and 24 h following the start of infusion. On Day 2 and Day 8, blood samples
will be collected 5, 10, 15 and 30 min and 1, 2, 3, 4, 6, 8, 10, 12 and 16 h following
completion of the 24-h infusion period.
Blood will be collected for evaluation of cytokine, chemokine, insulin and free fatty acid
(FFA) serum levels, and for evaluation of STAT4 phosphorylation status of monocytes, on Days
1-2 and Days 7-8 within 0.5 h prior to the start of infusion (time 0) and 24 h following the
start of infusion.
Study Endpoints Plasma LSF concentrations and PK assessments: Blood will be collected for
determination of plasma LSF concentration at time points noted previously. PK parameters
will include AUC0-t, AUC0-inf, Cmax, Tmax, t1/2, kel, CL, Vdss and F.
PD assessments: Blood will be collected for determination of serum cytokine, chemokine,
insulin and FFA levels at time points noted previously.
Safety outcome measures: Safety will be based on AEs, vital signs assessments, resting
12-lead ECG evaluations, physical examination findings and clinical laboratory test results.
;
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |